6 analysts have expressed a variety of opinions on SpringWorks Therapeutics (NASDAQ:SWTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...

Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for SpringWorks Therapeutics (NASDAQ:SWTX) revealed 9 unusual trades. Delving into ...

SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker has attracted the attention of a biopharma bigwig from overseas.

STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. After months of discussion, Germany’s Merck KGaA said Monday it would buy ...

Add Yahoo as a preferred source to see more of our stories on Google. Apr. 21—LISBON — As Springworks Farm celebrates 10 years in business this year, head grower Brady Sinclair is notching his first ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Seeking to enhance its presence in cancer drugs and the US, the German drug company Merck KGaA is buying the oncology biotech SpringWorks Therapeutics for $3.9 billion. The deal is expected to close ...

(Reuters) -SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the ...

SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully ...